Skip to main content

Table 3 Adjusted association between hepatic adverse events and episodes groups in the AL arm

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters

aOR (95% CI) with hepatic adverse events

Elevated ALT

LR-p value: 0.025

Elevated AST

LR-p: <0.001

Elevated total bilirubin

LR-p: 0.001

Episode groups

   

 First treatment

1

1

1

 Retreatment

0.24 (0.08; 0.70) *

0.16 (0.06; 0.41) ***

2.48 (1.31; 4.69) **

Age

0.96 (0.87; 1.05)

0.83 (0.73;0.93) **

1.05 (1.02; 1.09) **

Sex

   

 Female

1

1

1

 Male

1.96 (0.67; 5.77)

0.80 (0.34; 1.84)

1.04 (0.61; 1.75)

  1. AL: artemether–lumefantrine; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; LR-p: likelihood ratio test’s p-value; aOR: adjusted odds ratio; CI: Confidence interval;
  2. * p < 0.05; ** p < 0.01; *** p < 0.001